Published in Leukemia on January 01, 2004
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol (2012) 1.40
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia (2010) 1.34
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica (2009) 1.31
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res (2009) 1.09
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica (2011) 1.06
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol (2006) 1.00
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia (2013) 0.96
Recent Advances in the 5q- Syndrome. Mediterr J Hematol Infect Dis (2015) 0.94
Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica (2009) 0.89
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion. Haematologica (2010) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
An uncommon case of an adult with del(5)(q) in acute lymphoblastic leukemia. Indian J Hum Genet (2012) 0.86
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica (2010) 0.84
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer (2009) 0.83
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol (2012) 0.82
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia (2015) 0.80
Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. J Blood Med (2010) 0.79
PP2A: The Achilles Heal in MDS with 5q Deletion. Front Oncol (2014) 0.79
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. Haematologica (2011) 0.78
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). Br J Haematol (2015) 0.76
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. Haematologica (2014) 0.76
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica (2011) 0.76
A case of refractory thrombocytopenia with 5q deletion: myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura. Ann Lab Med (2014) 0.76
The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores. J Med Life (2014) 0.75
Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report. North Clin Istanb (2015) 0.75
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden. Leukemia (2015) 0.75
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med (2014) 0.75
Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes. Ther Clin Risk Manag (2007) 0.75
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
A physical map of the human genome. Nature (2001) 12.39
EST comparison indicates 38% of human mRNAs contain possible alternative splice forms. FEBS Lett (2000) 4.96
Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 4.41
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Noise enhancement of information transfer in crayfish mechanoreceptors by stochastic resonance. Nature (1993) 2.81
The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood (2001) 2.77
Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem (1992) 2.31
MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A (1997) 2.01
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
Medical treatment of acute ischaemic stroke. Lancet (1992) 1.94
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89
Delay time for influenza virus hemagglutinin-induced membrane fusion depends on hemagglutinin surface density. J Virol (1991) 1.87
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia (2013) 1.71
All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood (1997) 1.71
Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood (1995) 1.64
Gating kinetics of pH-activated membrane fusion of vesicular stomatitis virus with cells: stopped-flow measurements by dequenching of octadecylrhodamine fluorescence. Biochemistry (1990) 1.63
Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res (1998) 1.60
A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma (2007) 1.58
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant (2005) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Molecular characterization of Mycobacterium paratuberculosis isolates from sheep, goats, and cattle by hybridization with a DNA probe to insertion element IS900. J Clin Microbiol (1996) 1.52
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
A novel 3D wavelet-based filter for visualizing features in noisy biological data. J Microsc (2005) 1.50
Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol (2005) 1.49
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
A clinical pilot study of fresh frozen plasma versus human albumin in paediatric craniofacial repair. J Int Med Res (2008) 1.48
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer (2010) 1.47
Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol (1997) 1.46
Two types of acquired idiopathic sideroblastic anaemia (AISA) Br J Haematol (1990) 1.45
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia (1992) 1.45
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leuk Res (2000) 1.42
Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus. Nephron (1990) 1.42
Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy (2004) 1.41
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia (2006) 1.40
Increases of sICAM-1 during neutropenic pneumonia in leukemic patients. Leukemia (1997) 1.39
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38
Delivery type and neonatal mortality among 10,749 breeches. Am J Public Health (1986) 1.38
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia (2013) 1.37
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia (2003) 1.37
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood (2001) 1.36
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia (2008) 1.35
A dissection of steps leading to viral envelope protein-mediated membrane fusion. Ann N Y Acad Sci (1991) 1.35
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia (2005) 1.32
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia (2002) 1.31
Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol (2001) 1.30
The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J Immunol (1998) 1.29
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol (2005) 1.27
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiol (1997) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Molecular characterization of Coxiella burnetii isolates. Epidemiol Infect (1998) 1.26
Management of acute myeloid leukemia in elderly patients. J Clin Oncol (1999) 1.25
Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood (1997) 1.24
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia (2013) 1.23
The 5q- syndrome. Hematology (2004) 1.23
Linkage of determinants for streptogramin A, macrolide-lincosamide-streptogramin B, and chloramphenicol resistance on a conjugative plasmid in Enterococcus faecium and dissemination of this cluster among streptogramin-resistant enterococci. Int J Med Microbiol (2000) 1.23
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Polymorphism in DNA restriction patterns of Coxiella burnetii isolates investigated by pulsed field gel electrophoresis and image analysis. Eur J Epidemiol (1993) 1.22
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol (2001) 1.21
Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant (2009) 1.21
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia (2007) 1.20
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood (1996) 1.20
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia (2000) 1.18
Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood (2001) 1.17
Is plasmid based differentiation of Coxiella burnetii in 'acute' and 'chronic' isolates still valid? Eur J Epidemiol (1994) 1.16
Whole body hyperthermia: a secure procedure for patients with various malignancies? Intensive Care Med (1999) 1.15
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology (2003) 1.14
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res (2000) 1.14